Get the Stockscreener App
34.36
2.31%
0.7752
Indivior Pharmaceuticals Inc stock is traded at $34.36, with a volume of 866.98K.
It is up +2.31% in the last 24 hours and down -5.12% over the past month.
Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs for treatment of substance use disorders and other serious mental illnesses. Its products include, Sublocade, Perseris, Suboxone, Opvee among others. The vast majority of Indivior's revenue is generated in the United States, followed by United Kingdom and the rest of the world.
See More
Previous Close:
$33.58
Open:
$33.58
24h Volume:
866.98K
Relative Volume:
0.36
Market Cap:
$4.30B
Revenue:
$1.12B
Net Income/Loss:
$5.00M
P/E Ratio:
3,435.52
EPS:
0.01
Net Cash Flow:
$-383.00M
1W Performance:
+4.27%
1M Performance:
-5.12%
6M Performance:
+100.45%
1Y Performance:
+185.83%
1-Day Range:
$33.54
$34.64
1-Week Range:
$32.66
$34.64
52-Week Range:
$7.62
$38.00
Indivior Pharmaceuticals Inc Stock (INDV) Company Profile
Name
Indivior Pharmaceuticals Inc
Sector
Phone
804-379-1090
Address
234 BATH ROAD, SLOUGH, BERKSHIRE
Compare INDV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INDV
Indivior Pharmaceuticals Inc
|
34.35 | 4.20B | 1.12B | 5.00M | -383.00M | 0.01 |
|
ZTS
Zoetis Inc
|
125.36 | 54.61B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.86 | 52.47B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.43 | 46.18B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.89 | 36.87B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
473.02 | 20.38B | 3.08B | 1.24B | 1.07B | 25.61 |
Indivior Pharmaceuticals Inc Stock (INDV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Initiated | H.C. Wainwright | Buy |
| Jul-22-25 | Resumed | Jefferies | Buy |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jul-23-24 | Initiated | Piper Sandler | Overweight |
| Apr-03-24 | Initiated | Craig Hallum | Buy |
| Jul-13-23 | Initiated | Northland Capital | Outperform |
View All
Indivior Pharmaceuticals Inc Stock (INDV) Latest News
Indivior completes redomiciliation from UK to US By Investing.com - Investing.com Nigeria
Indivior announces completion of redomiciliation to U.S. - TipRanks
Indivior (INDV) Completes Move from UK to US, Listed on Nasdaq - GuruFocus
Indivior completes redomiciliation from UK to US - Investing.com
Indivior Announces Completion of Redomiciliation to the United States - GlobeNewswire
Indivior PLC: Can a Focused Addiction-Treatment Portfolio Power the Next Wave of Growth? - AD HOC NEWS
Is Indivior PLC forming higher highs and higher lowsJuly 2025 Macro Moves & Weekly Hot Stock Watchlists - mfd.ru
(INDV) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Indivior’s 2026 Revenue Guidance Tightens Expectations Might Change The Case For Investing In Indivior (INDV) - Yahoo Finance
Aug Selloffs: Can Indivior PLC stock outperform in a bear marketJuly 2025 Technicals & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Indivior PLC: Can a Focused Addiction-Treatment Specialist Win the Next Decade of Mental Health Phar - AD HOC NEWS
Grail and Indivior PLC come out on top in healthcare quant picks ahead of Q4 earnings - MSN
Market Wrap: Will WNEB outperform small cap indexes2025 Sector Review & Trade Opportunity Analysis - baoquankhu1.vn
Indivior (NASDAQ:INDV) Downgraded to "Hold" Rating by Zacks Research - MarketBeat
Indivior PLC: How a Specialist Addiction Franchise Is Quietly Rebuilding a Global Pharma Contender - AD HOC NEWS
Indivior (INDV) Price Target Increased by 13.21% to 43.71 - Nasdaq
Q1 Earnings Forecast for Indivior Issued By HC Wainwright - MarketBeat
Portfolio Update: Is now the right time to enter Indivior PLCJuly 2025 Chart Watch & Accurate Entry/Exit Alerts - baoquankhu1.vn
Indivior PLC (INDV) Stock Analysis: Exploring a 24% Upside Potential in the Healthcare Sector - DirectorsTalk Interviews
Aug Setups: Does Indivior PLC stock trade at a discount to peersMarket Activity Summary & Safe Capital Growth Tips - Bộ Nội Vụ
Risks Report: Will Indivior PLC stock remain a Wall Street favorite2025 Technical Patterns & Free Real-Time Volume Trigger Notifications - Bộ Nội Vụ
Sanofi's Teizeild Gets EU Approval for Treating Type 1 Diabetes - Finviz
HC Wainwright Estimates Indivior's Q2 Earnings (NASDAQ:INDV) - MarketBeat
51,426 Shares in Indivior PLC $INDV Purchased by KLP Kapitalforvaltning AS - MarketBeat
Volume Recap: Is Indivior PLC forming higher highs and higher lows2025 Market Sentiment & Verified Entry Point Signals - baoquankhu1.vn
TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug - Finviz
Take the Zacks Approach to Beat the Markets: Indivior, FIGS & Ulta Beauty in Focus - Yahoo Finance
Indivior stock price target raised to $48 from $35 at H.C. Wainwright - Investing.com Nigeria
INDV: Analyst Raises Price Target to $48.00, Maintains Buy Ratin - GuruFocus
Naloxone Market Is Going to Boom |EMERGENT, Indivior PLC, Akorn, Inc - openPR.com
Indivior PLC (INDV) Announces Full-Year 2026 Financial Guidance - Finviz
Indivior (NasdaqGS:INDV) Valuation Check After Strong Long Term Returns And Recent Price Consolidation - Yahoo Finance
Indivior PLCOrdinary Shares (NQ: INDV - FinancialContent
Indivior forecasts 11% SUBLOCADE growth, 35% EBITDA increase for 2026 By Investing.com - Investing.com Nigeria
Craig-Hallum raises Indivior stock price target to $50 on strong 2026 outlook - Investing.com Nigeria
Aug Closing: Why hedge funds are buying Indivior PLC stockWall Street Watch & Safe Entry Trade Signal Reports - moha.gov.vn
Can Indivior PLC stock double in next 5 years2025 Volume Leaders & Safe Entry Point Alerts - ulpravda.ru
Why Indivior PLC (2IVB) stock is a strong analyst pickWeekly Risk Summary & Safe Entry Point Identification - ulpravda.ru
Why retail investors pile into Indivior PLC stockJuly 2025 Momentum & Fast Moving Market Watchlists - ulpravda.ru
Is Indivior PLC stock a top pick in earnings season2025 Macro Impact & Fast Exit Strategy with Risk Control - ulpravda.ru
What margin trends mean for Indivior PLC stockWeekly Trade Report & Real-Time Chart Pattern Alerts - ulpravda.ru
GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug - Finviz
Published on: 2026-01-08 20:56:58 - ulpravda.ru
How Indivior PLC stock performs during Fed tightening cycles2025 Key Lessons & Stepwise Entry/Exit Trade Alerts - ulpravda.ru
What analyst consensus says on Indivior PLC stock2025 AllTime Highs & Daily Technical Stock Forecast Reports - ulpravda.ru
Indivior Issues FY 2026 Financial Guidance - Nasdaq
Indivior shares rise after FY26 guidance tops consensus expectations By Investing.com - Investing.com Nigeria
Indivior PLC Provides Earnings Guidance for the Full Year 2026 - marketscreener.com
Indivior Expects Up to $1.20 Billion in 2026 Net Revenue - MarketScreener
(INDV) Indivior Expects 2026 Revenue Range $1.13B$1.2B, vs. FactSet Est of $1.19B - MarketScreener
Indivior forecasts 11% SUBLOCADE growth, 35% EBITDA increase for 2026 - Investing.com
Indivior Pharmaceuticals Inc Stock (INDV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):